Advanced Medical Solutions Grp PLC US approvals for RESORBA suture range (4612E)
November 04 2015 - 2:00AM
UK Regulatory
TIDMAMS
RNS Number : 4612E
Advanced Medical Solutions Grp PLC
04 November 2015
Advanced Medical Solutions Group plc
("AMS" or the "Group")
510(k) Premarket notifications to market sutures in the US
Winsford, UK, 4 November 2015 - Advanced Medical Solutions Group
plc (AIM: AMS.L), the surgical and advanced woundcare specialist
company, today announces that it has received notice of further
Premarket 510(k) approvals, successfully adding to its first US
suture approval from early 2015, thereby covering the vast majority
of the rest of the suture product portfolio. With only one more
suture type still awaiting US market approval, the Group is now
well positioned to launch a comprehensive range of sutures into the
US in mid 2016 through a combination of its branded and unbranded
routes to market.
Chris Meredith, Chief Executive Officer of Advanced Medical
Solutions, said: "We are pleased that we are now in a position to
access the US surgical suture market which is estimated to be in
excess of $1billion in size and dominated by a few major brands.
This continues our strategy of extending our portfolio into new
markets and gaining US approval for the RESORBA(R) product range
has been a strategic target of the Group since we acquired the
business late 2011. The most recent approvals provide a new,
significant opportunity for the Group."
- Ends -
For further information, please visit www.admedsol.com or
contact:
Advanced Medical Solutions Group Tel: +44 (0)
plc 1606 545508
Chris Meredith, Chief Executive
Officer
Mary Tavener, Group Finance Director
Consilium Strategic Communications Tel: +44 (0)
20 3709 5700
Mary-Jane Elliott / Jonathan
Birt / Matthew Neal / Ivar Milligan
About Advanced Medical Solutions Group plc - see
www.admedsol.com
AMS is a world-leading independent developer and manufacturer of
innovative and technologically advanced products for the global
surgical, wound care and wound closure markets, focused on quality
outcomes for patients and value for payors. AMS has a wide range of
products that include silver alginates, alginates, foams, tissue
adhesives, sutures and haemostats, which it markets under its
brands ActivHeal(R) , LiquiBand(R) and RESORBA(R) as well as
supplying under white label.
AMS's products, manufactured out of two sites in the UK, one in
the Netherlands, two in Germany and one in the Czech Republic, are
sold in 65 countries via a network of multinational or regional
partners and distributors, as well as via AMS's own direct sales
forces in the UK, Germany, the Czech Republic and Russia.
Established in 1991, the Group has approximately 470 employees. For
more information please see www.admedsol.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCDMMGMZFGGKZZ
(END) Dow Jones Newswires
November 04, 2015 02:00 ET (07:00 GMT)
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From Apr 2023 to Apr 2024